* it’s administered as a once-a-day pill.
* Preclinical studies suggest it may protect retinal ganglion cells by reversing synapse loss, possibly offering a new treatment for glaucoma and other retinal synaptopathies.
Lisa Park is a leading technology journalist with 11 years of experience covering Silicon Valley, emerging technologies, and digital innovation. Lisa holds a Master’s in Computer Science and Her expertise spans artificial intelligence, blockchain technology, cybersecurity, and venture capital. She has exclusive access to tech executives, startup founders, and industry insiders, making her a trusted voice in technology reporting.
This news is powered by News Directory 3 
